Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and a Waiver under 18 U.S.C. §208(b)(3)

John Carpenter, M.D.			
Committee:	Oncologic Drugs Advisory Committee		
Meeting Date:	September 7, 2006		
I acknowledge that contingent upon public disclosure of the financial interest listed below, related to new drug application (NDA) 21-660, Abraxane (paclitaxel protein-bound particles for injectable suspension)(albumin-bound), sponsored by Abraxis BioScience, Inc., including trial design issues for adjuvant treatment of node-positive breast cancer, I am eligible to receive a waiver under 18 U.S.C. §208(b)(3).			
Type of Interest	Nature	Magnitude	
Unrelated Speaker's Bureau	Competitor	Less than \$10,001 per y	ear/
• •	•	ublicly available on my beha terest, the waiver is not valid	
<u>/s/</u>		8/4/06	
Signature		Date	